嵌合抗原受体 T 细胞疗法治疗 B 淋巴细胞白血病的现状。
The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia.
机构信息
Division of Oncology, Cancer Immunotherapy Program, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Division of Oncology, Cancer Immunotherapy Program, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Hematol Oncol Clin North Am. 2023 Dec;37(6):1041-1052. doi: 10.1016/j.hoc.2023.06.003. Epub 2023 Jul 26.
Over the past decade, CAR T cell therapy has transformed the treatment of relapsed or refractory B-ALL in children and adults. CD19-directed CAR T cells can induce complete remissions in a large majority of patients with B-ALL, and up to half of these patients will go on to maintain durable remissions. However, significant challenges remain for patients who relapse or do not respond. This review will discuss the history of CAR T cell therapy for B-ALL, the treatment considerations for CAR T cell recipients, and current clinical trials and future directions for CAR T cell therapy in B-ALL.
在过去的十年中，嵌合抗原受体 T 细胞（CAR T 细胞）疗法已经改变了儿童和成人复发或难治性 B 细胞急性淋巴细胞白血病（B-ALL）的治疗方法。针对 CD19 的 CAR T 细胞可以使大多数 B-ALL 患者获得完全缓解，其中多达一半的患者将持续缓解。然而，对于复发或无反应的患者，仍然存在重大挑战。本文将讨论 CAR T 细胞治疗 B-ALL 的历史、CAR T 细胞受者的治疗注意事项，以及目前 CAR T 细胞治疗 B-ALL 的临床试验和未来方向。
Zotero 插件